Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 7Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Nasopharyngeal Carcinoma 1Medulloblastoma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 11Gemcitabine 10Radiotherapy, Intensity-Modulated 6Capecitabine 6Drug Therapy 3Docetaxel 3toripalimab 2spartalizumab 2pembrolizumab 2nimotuzumab 2fludarabine 2atezolizumab 2Specimen Handling 2Platinum 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Fluorouracil 2Disulfides 2Cyclophosphamide 2Carboplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2tislelizumab 1sintilimab 1penpulimab 1olaparib 1fludarabine phosphate 1dehydroftorafur 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Nasopharyngeal Carcinoma × Induction Chemotherapy × Clear all
NCT05304468 2025-03-21

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Sun Yat-sen University

Phase 3 Active not recruiting
452 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡